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ABSTRACT  
Valproate is a commonly used mood stabilizer. One of the important and rare side effects of valproate is hyperammonemia leading to delirium and 
hepatic encephalopathy. Valproate-induced delirium is commonly mistaken for worsening of manic symptoms or psychosis. We hereby report a 
case of bipolar affective disorder who was on a therapeutic dose of valproate monotherapy developed altered mental status where we found 
elevated levels of plasma ammonia which decreased after the discontinuation of valproate and with normal levels of serum valproate, LFT’s, EEG 
and imagings. This case report emphasises on the need to consider plasma ammonia levels in patients with altered mental status receiving 
valproate in addition to other investigations. 
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Valproate is a commonly used mood stabiliser and an anticonvulsant. 
Valproate-induced delirium due to hyper-ammonemia is a rare 
adverse effect ascribed to valproate. Often, valproate-induced 
hyperammonemia occurs when the patient is receiving additional 
medications like topiramate, has focal neurological deficits or has 
elevated liver function tests [1–4]. Typically, such hyperammonemia 
occurs when valproate is initiated. We presented here the case of a 
valproate-induced delirium due to hyperammonemia in a patient 
with bipolar disorder when valproate dose was increased.  
CASE REPORT 
A 58 y old male with the bipolar affective disorder was on a maintenance 
dose of valproate 500 mg per day past 3 mo and was increased to 1000 
mg per day 4 d back. He presented with altered mental status, irrelevant 
and slurred speech, drowsiness, disorientation, difficulty in walking, 
altered sleep pattern and abdominal discomfort. There was no history of 
fever, headache, vomiting, hypertension, and diabetes, weakness of 
limbs, seizures, substance abuse, and head injury prior to the admission. 
There were no focal deficits and other systems were normal and 
hemodynamically stable.  
All investigations were done to rule out organicity. Blood sugars, 
serum electrolytes, LFT, RFT, calcium, magnesium, CBC, serum 
valproic acid, ECG, EEG were found to be normal, but plasma 
ammonia levels were elevated to 190 µmole/l (n = 11-32 µmole/l). 
Valproate was stopped and the patient showed rapid recovery and 
improvement on the 2nd day with relevant, coherent talking 
oriented, no drowsiness, and sleep cycle was normal and abdominal 
discomfort was relieved. Repeat plasma ammonia was done on 5th 
day and it was decreased to 50 µmole/l. 
DISCUSSION 
Valproate-induced hyperammonemia is a rare condition that 
typically occurs at the initiation of treatment with valproate, 
especially in the presence of predisposing factors like use of 
topiramate. Liver function abnormality is commonly found in such 
circumstances. In the present case, encephalopathy was present 
without features of liver dysfunction. The encephalopathy occurred 
when the dose of valproate was increased from 500 mg per day to 
1000 mg per day, still within the therapeutic range. The 
hyperammonemia could be ascribed to valproate, as increased 
ammonia levels were present during the phase of altered mental 
status, and decreased with cessation of valproate.  
Valproate-induced hyperammonemia is usually an acute and 
transient phenomenon that could become life threatening if left 
untreated [5]. It presents with disorientation, drowsiness, lethargy, 
gait and sleep disturbances and varying presentation of altered 
mental status. Focal neurological features have also been described 
in patients with such a condition. Various mechanisms have been 
proposed for the development of valproate-induced hyper-
ammonemia. Valproate-induced carnitine deficiency and inhibition 
of carbamoyl phosphate synthetase enzyme leading to urea cycle 
disturbances is one of the common mechanisms [6]. Another 
mechanism proposed is inhibition of the release of glutamine 
causing increased intracellular osmolality resulting in astrocyte 
swelling, cerebral oedema and subsequently increased intracranial 
pressure [7]. Valproate stimulation of renal mitochondria may lead 
to increased glutamate uptake and release of ammonia in serum [8]. 
Concomitant use of other drugs like topiramate, aspirin, and 
cimetidine may increase the non-protein bound fraction of valproate 
that may lead to hyperammonemia. Comorbid renal failure and 
hypoalbuminemia may also contribute to the genesis of valproate-
induced hyperammonemia. 
CONCLUSION 
To conclude, the present case suggests that valproate-induced 
encephalopathy should be considered when clouding of consciousness 
and disorientation occurs in the patient on dose increment who is 
otherwise on stable doses of valproate. Such an encephalopathy can 
occur without hepatic dysfunction. Prompt discontinuation of 
valproate may help in rapid correction of the condition, which can be 
corroborated with monitoring of plasma ammonia levels.  
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